midazolam has been researched along with rilpivirine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, FE; Clercq, E; Hao, QQ; Ling, X; Pannecouque, C | 1 |
| Burhenne, J; Carls, A; Haefeli, WE; Hohmann, N; Mikus, G; Reinhard, R; Schnaidt, S; Witt, L | 1 |
1 trial(s) available for midazolam and rilpivirine
| Article | Year |
|---|---|
Treatment with rilpivirine does not alter plasma concentrations of the CYP3A substrates tadalafil and midazolam in humans.
Topics: Adolescent; Adult; Anti-HIV Agents; Cytochrome P-450 CYP3A; Drug Interactions; Female; Healthy Volunteers; Humans; Male; Midazolam; Middle Aged; Phosphodiesterase 5 Inhibitors; Plasma; Rilpivirine; Tadalafil; Young Adult | 2016 |
1 other study(ies) available for midazolam and rilpivirine
| Article | Year |
|---|---|
Expansion of the S-CN-DABO scaffold to exploit the impact on inhibitory activities against the non-nucleoside HIV-1 reverse transcriptase.
Topics: Animals; Anti-HIV Agents; HIV Reverse Transcriptase; HIV-1; Mice; Molecular Docking Simulation; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2022 |